RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Clinical trials for RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for patients with Hard-to-Treat blood cancer
Disease control OngoingThis study is testing an experimental drug called zilovertamab vedotin for people with an aggressive type of blood cancer called diffuse large B-cell lymphoma that has returned or hasn't responded to at least two prior treatments. The main goals are to see if the drug shrinks tum…
Matched conditions: RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Apr 02, 2026 05:26 UTC
-
New drug combos tested for Tough-to-Treat blood cancer
Disease control TerminatedThis study aimed to test the safety and effectiveness of a drug called selinexor when combined with other treatments for adults with an aggressive type of blood cancer (DLBCL) that has returned or stopped responding to prior therapies. The first part of the study would find the s…
Matched conditions: RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Karyopharm Therapeutics Inc • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC